<DOC>
	<DOCNO>NCT03026933</DOCNO>
	<brief_summary>To examine variation rate Non-HDL KI1107 comparison Rosuvastatin monotherapy .</brief_summary>
	<brief_title>Evaluate Efficacy Safety KI1107 Patients Whose TG Level Not Adequately Controlled With Rosuvastatin Calcium Monotherapy While LDL-C Properly Controlled</brief_title>
	<detailed_description>Study design : Randomly assign two group ( KI1107 Rosuvastatin monotherpy ) 4 week run-in period prescribe KI1107 Rosuvastatin 8 week .</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Inclusion criterion : Screening Visit Age : 1980 High risk cardiovascular disease accord NCEP APT III TG≥130mg/dL 160mg/dL &gt; LDLC≥100mg/dL subject take statin 4 week 500mg/dL &gt; TG≥200mg/dL LDLC &lt; 110mg/dL subject take statin 4 week Baseline Visit 500mg/dL &gt; TG≥200mg/dL LDLC &lt; 110mg/dL Reduction LDLC dompairng screen visit Exclusion criterion : The patient history acute artery disease within 3 month The patient history operation revasculatiation aneurysm within 6 month The patient history Unexplained myaliga diagnose myalgia rhabdomyolysis The patient histories Effectable disease procedrue clinical trial result</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>